- Conditions
- Psychomotor Agitation
- Interventions
- Quetiapine
- Drug
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2161–2184
of 6,233
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Coronary Disease, Atherosclerosis, Myocardial Infarction
- Interventions
- Simvastatin and Extended-Release niacin, Simvastatin
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 13 more
- Conditions
- Psychosis, Schizophrenia, Schizoaffective Disorder, Psychosis Nos/Other, Bipolar Disorder
- Interventions
- Care Coordination, Individual Peer Support, Digital Outreach, Cognitive Remediation, Multi-Family Group Therapy
- Behavioral
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- Belmont, Massachusetts • Boston, Massachusetts • Cambridge, Massachusetts + 1 more
- Conditions
- Locally Advanced Unresectable Pancreatic Adenocarcinoma
- Interventions
- Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
- Combination Product
- Lead sponsor
- Impact Biotech Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Duarte, California • Irvine, California
- Conditions
- Breast Neoplasms
- Interventions
- PF-06804103, PF-06804103 + Palbociclib +Letrozole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Los Angeles, California • Santa Monica, California + 14 more
- Conditions
- Sickle Cell Disease
- Interventions
- Motixafortide
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Bethesda, Maryland • Memphis, Tennessee
- Conditions
- Healthy
- Interventions
- [14C]-LOXO-305, LOXO-305
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Avoidant/Restrictive Food Intake Disorder (ARFID)
- Interventions
- Cognitive-Behavioral Therapy for Avoidance Restrictive Food Intake Disorder (CBT-AR), Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Gastrointestinal Inflammation Associated With CVID, CVID Enteropathy
- Interventions
- Stelara (ustekinumab)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Smoking Cessation
- Interventions
- Nicotine patch, in-person counseling and quitline counseling, Preparation Nicotine Mini-Lozenges, Combination NRT (nicotine patch + nicotine mini-lozenges), Intensive In-Person Cessation Counseling, Extended Maintenance Counseling Calls, Automated Adherence Calls
- Drug · Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Advanced Solid Tumor
- Interventions
- DS-1103a, T-DXd
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 5
- States / cities
- Sarasota, Florida • New York, New York • Providence, Rhode Island + 2 more
- Conditions
- Colorectal Carcinoma, Lynch Syndrome
- Interventions
- Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biospecimen Collection, Endoscopic Biopsy, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, Questionnaire Administration
- Biological · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Duarte, California • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Advanced Solid Tumors
- Interventions
- BMS-986408, Nivolumab, Ipilimumab, Platinum-doublet chemotherapy, Rabeprazole
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Hackensack, New Jersey • Houston, Texas
- Conditions
- Eye Movement
- Interventions
- NeuraLight
- Other
- Lead sponsor
- NeuraLight
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 2,000 participants
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
- Conditions
- Severe Aplastic Anemia (SAA)
- Interventions
- REGN7257
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Breast surgery
- Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 10
- States / cities
- Hartford, Connecticut • Ann Arbor, Michigan • Basking Ridge, New Jersey + 7 more
- Conditions
- Genetics Disease, Genetics/Birth Defects, Genetic Predisposition to Disease
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 0 Days to 99 Years
- Enrollment
- 631 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 10
- States / cities
- Mobile, Alabama • Miami, Florida • Boston, Massachusetts + 6 more
- Conditions
- Asthma
- Interventions
- School-Based Asthma Care for Teens (SB-ACT), Directly Observed Therapy, Asthma Education
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 12 Years to 16 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Lymphoma
- Interventions
- milatuzumab, veltuzumab, Correlative/Special Studies, Quantitative T-, B-, and NK cell subsets, Pharmacokinetics, Human Anti-Human Antibodies, veltuzumab and milatuzumab
- Biological · Procedure
- Lead sponsor
- Beth Christian
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Hypertension, Health Behavior, Healthcare Patient Acceptance, Patient Engagement, Adherence, Patient
- Interventions
- Remote Patient Monitoring, Self-monitoring of hypertension-related factors, Immediate financial incentives, Delayed financial incentives
- Behavioral
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Bastrop, Louisiana • Shreveport, Louisiana
- Conditions
- Asthma, Allergic
- Interventions
- REGN3500, Dupilumab, Placebo, Fluticasone propionate
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
- Interventions
- Obinutuzumab, Liposomal ARA-C, Ifosfamide, Carboplatin, Etoposide
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 3 Years to 31 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Valhalla, New York
- Conditions
- Multiple Myeloma
- Interventions
- Siltuximab11 mg/kg, Siltuximab 8.3 mg/kg or 11 mg/kg, Velcade (bortezomib), Melphalan, Prednisone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
- Interventions
- BMS-986500, Palbociclib, Fulvestrant
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Fullerton, California • Greenbrae, California + 11 more